Price, David http://orcid.org/0000-0002-9728-9992
Jenkins, Christine
Hancock, Kerry
Vella, Rebecca
Heraud, Florian
Le Cheng, Porsche
Murray, Ruth
Beekman, Maarten
Bosnic-Anticevich, Sinthia
Botini, Fabio
Carter, Victoria
Catanzariti, Angelina
Doan, Joe
Fletton, Kirsty
Kichkin, Ata
Le, Thao
Le Lievre, Chantal
Lau, Chi Ming
Novic, Dominique
Pakos, John
Ranasinghe, Kanchanamala
Roussos, Alexander
Samuel-King, Josephine
Sharma, Anita
Stewart, Deb
Willet, Bruce
Bateman, Eric
Campbell, Rob
Liu, Ying
O’Sullivan, Nicole
Rejda, Ondrej
Sugg, Lisa
James, Steph
Dhillon, Kiran
Jones, Sophie
,
Funding for this research was provided by:
Optimum Patient Care Australia
AstraZeneca
Article History
Received: 3 August 2023
Accepted: 20 November 2023
First Online: 4 February 2024
Declarations
:
: Kerry L. Hancock has received speakers’ fees, consulting honoraria and/or travel grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Menarini Australia, Mylan and Novartis. Sinthia Bosnic-Anticevich has received honorarium for participation in expert advisory boards and given lectures for Teva Pharmaceuticals, AstraZeneca, GSK, Meda, Mundipharma, Sanofi, Mylan and received unrestricted research grants from Mylan, AstraZeneca, Teva and Mundipharma International. Angelina Catanzariti is an employee of AstraZeneca. Christine Jenkins, Joe Doan, Ata Kichkin, Chi Ming Lau, Dominique Novic, John Pakos, Kanchanamala Ranasinghe, Josephine Samuel-King, Bruce Willet, and Thao Le declares no conflict of interest. Anita Sharma is a practising Primary Care Physician and Senior Lecturer, School of Clinical Medicine-Primary Care Clinical Unit, University of Queensland. She supervises clinical training of primary care doctors and serves on advisory boards for Diabetes, Heart Failure and Osteoporosis for Novartis, Merck Sharp & Dohme and Boehringer Ingelheim, Eli Lilley and Amgen. Eric Bateman has received honorarium for participation in advisory boards from ALK, AstraZeneca, Novartis, Regeneron and Sanofi Aventis, and for giving lectures for AstraZeneca, Chiesi, Menarini, Novartis, Orion, Regeneron and Sanofi Aventis. He is a member of the Board and Science Committee of GINA. Maarten JHI Beekman was an employee of AstraZeneca at time of study conduct. Rebecca Vella, Florian Heraud, Porsche Le Cheng, Fabio Botini, Thao Le, Chantal Le Lievre, Alex Roussos are employees of Optimum Patient Care Australia. Ruth Murray is a consultant for the Observational and Pragmatic Research Institute. Victoria Carter is an employee of Optimum Patient Care Global and has 5% shareholding of Optimum Patient Care Australia. Kirsty Fletton is an employee of Optimum Patient Care United Kingdom. David Price has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; consultancy agreements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside Practice, GlaxoSmithKline, Medscape, Viatris, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, Teva Pharmaceuticals.; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline.
: This study was approved by the Anonymised Data Ethics Protocols and Transparency (ADEPT) committee—the independent scientific advisory committee for the OPCRDA (ADEPT1819). The study was designed, implemented, and reported in compliance with the European Network Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) Code of Conduct (EMA 2014; EUPAS105682) All patients provided consent sharing their de-identified data with OPCRDA for research purposes. As noted, the dataset supporting the conclusions of this article was derived from the Optimum Patient Care Research Database Australia (ExternalRef removed). The OPCRDA has ethical approval from The Royal Australian College of General Practitioners (RACGP) National Research and Evaluation Ethics Committee (NREEC) to hold and process anonymised research data (NREEC Reference: 18-013).